



Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference

November 25, 2019

FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 25, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the Evercore ISI 2nd Annual HealthCONx Conference.

- Location: Boston, MA
- Presentation date: Wednesday December 4, 2019
- Presentation time: 8:00 a.m. ET

A live audio webcast and archive of the presentation will be available at <http://ir.mirumpharma.com>

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). For more information, visit MirumPharma.com. Follow Mirum on [Twitter](#), [Facebook](#) and [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191125005078/en/>

Source: Mirum Pharmaceuticals, Inc.

Media Contact:

Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi@canalecomm.com

Investor Contact:

Ian Clements, Ph.D.
650-667-4085
ir@mirumpharma.com